Compare GSK plc (GSK) vs Microchip Technology Inc. (MCHP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Microchip Technology Inc. — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while Microchip Technology Inc. trades at $75.94 (market cap $41.01B). The key difference: GSK plc is far larger — about 2.2× Microchip Technology Inc.'s market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Microchip Technology Inc. for 63 Days on average.
| GSK | MCHP | |
|---|---|---|
Market Cap | $91.88B | $41.01B |
Volume | 7,730,529 | 9,972,516 |
Sector | Health | Technology |
52-Week High | $61.18 | $102.97 |
52-Week Low | $43.24 | $49.02 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $111.88B | $46.13B |
Dividend Yield | 3.9% | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
Microchip Technology (MCHP) trades at $75.55, down 3.17% over the past day, with a bearish technical signal from moving averages. The company reported a net loss of -$500K in 2025 despite beating EPS estimates in recent quarters, though revenue declined to $4.40B. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios alongside the acquisition of Hailo to bolster edge AI capabilities.
MCHP faces near-term headwinds from profitability pressures and high debt, but long-term growth is supported by AI infrastructure demand and strategic expansions. Investment opportunities exist if operational improvements and market trends materialize, though risks include competitive intensity and execution challenges in a cyclical semiconductor market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →
